Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

54.86 +0.73 (+1.35%)

Streaming Delayed Price Updated: 1:09 PM EDT, Mar 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗

March 20, 2026

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗

March 20, 2026

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

Via The Motley Fool

Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks

March 19, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BioMarin Pharmaceutical (NASD...

Via StockStory

Topics Artificial Intelligence

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

March 16, 2026

Via Chartmill

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Q4 2025 Revenue Beat and EPS Miss ↗

February 23, 2026

Via Chartmill

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

January 24, 2026

Via Chartmill

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Emerges as a 'Decent Value' Candidate ↗

January 02, 2026

Via Chartmill

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗

March 16, 2026

Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.

Via The Motley Fool

This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗

March 16, 2026

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

Via The Motley Fool

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗

March 15, 2026

HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.

Via The Motley Fool

Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal ↗

December 19, 2025

Via Stocktwits

2 Mid-Cap Stocks with Exciting Potential and 1 We Question

March 12, 2026

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Via StockStory

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.

Via The Motley Fool

Topics Regulatory Compliance

2 Reasons to Like BMRN (and 1 Not So Much)

March 02, 2026

BioMarin Pharmaceutical currently trades at $61.02 per share and has shown little upside over the past six months, posting a middling return of 3.5%. Does th...

Via StockStory

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.

Via The Motley Fool

Topics Regulatory Compliance

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.

Via The Motley Fool

Topics Regulatory Compliance

BioMarin Pharmaceutical’s (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates

February 23, 2026

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 17% year on year to $874.6 million. The company expects the...

Via StockStory

Topics Earnings

BioMarin Pharmaceutical Earnings: What To Look For From BMRN

February 21, 2026

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results this Monday after market close. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence Government World Trade

Should You Buy BioMarin Pharmaceutical Before Feb. 18? ↗

January 31, 2026

There's no need to hurry in buying this biotech stock.

Via The Motley Fool

Topics Earnings

1 of Wall Street’s Favorite Stock with Exciting Potential and 2 We Find Risky

January 08, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

Topics Artificial Intelligence

The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity

January 06, 2026

The first week of 2026 has signaled a tectonic shift in the global financial landscape, as a wave of multi-billion dollar acquisitions has effectively ended the deal-making drought of the previous two...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

10 Magnificent Stocks That Can Make You Richer in 2026 ↗

January 05, 2026

A new year brings new opportunities to grow your wealth on Wall Street.

Via The Motley Fool

Topics Economy Stocks World Trade

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Via MarketMinute

Topics Economy Intellectual Property

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSE - CWAN), Katapult Holdings, Inc. (Nasdaq - KPLT), Janus Henderson Group plc (NYSE - JHG), Amicus Therapeutics, Inc. (Nasdaq

December 23, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

December 23, 2025

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 2.6% in the afternoon session after the stock's positive momentum continued as the company agreed to acquire Amicus Therapeutics...

Via StockStory

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

December 19, 2025

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 19% in the afternoon session after the company announced it agreed to acquire Amicus Therapeutics for approximately $4.8 billion...

Via StockStory

Topics Economy

Which stocks are gapping on Friday? ↗

December 19, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

1 Oversold Stock Primed to Rebound and 2 That Underwhelm

December 15, 2025

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling...

Via StockStory

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

December 08, 2025

BioMarin Pharmaceutical (BMRN) presents a compelling value investment case, trading at a significant discount to its biotech peers while showing strong profitability, financial health, and growth...

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.